Rodabe N Amaria - JoVE Visualize

Showing results (41-50 of 85) with videos related to

Pageof 9

Sort By:

Annals of Surgical Oncology|May 26, 2026

The Role of Adjuvant Primary Site Radiotherapy for Cutaneous Melanoma Patients with MicrosatellitosisAnjali Devireddy, Yifan Yi, Kelsey N Nordlund, et al.

Cancer|December 3, 2016

Clinicopathological features and clinical outcomes associated with TP53 and BRAF<sup>N</sup><sup>on-</sup><sup>V</sup><sup>600</sup> mutations in cutaneous melanoma patientsDae Won Kim, Lauren E Haydu, Aron Y Joon, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2020

Circulating Tumor Cells and Early Relapse in Node-positive MelanomaAnthony Lucci, Carolyn S Hall, Sapna P Patel, et al.

Oncoimmunology|August 15, 2025

Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanomaMerve Hasanov, Simin Kiany, Marie-Andrée Forget, et al.

Journal for Immunotherapy of Cancer|May 22, 2021

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanomaChantal Saberian, Rodabe N Amaria, Amer M Najjar, et al.

Cancer Discovery|March 3, 2018

A Preexisting Rare <i>PIK3CA</i><sup>E545K</sup> Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in <i>NRAS</i> Melanoma and Is Dependent on S6K1 SignalingGabriele Romano, Pei-Ling Chen, Ping Song, et al.

Nutrients|January 10, 2026

Investigating Chronic Toxicity, Diet, Patient-Reported Outcomes and the Microbiome in Immunotherapy-Treated Metastatic Melanoma Survivors: A New FrontierMargaux Robert, Satabdi Saha, Nazli Dizman, et al.

Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 15, 2018

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal MelanomaRené J Tavera, Marie-Andrée Forget, Young Uk Kim, et al.

Annals of Surgical Oncology|March 16, 2026

Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal DissectionJoshua Herb, Roland L Bassett, Carlos A Torres-Cabala, et al.

Cancers|November 13, 2021

Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade OutcomesRobert A Szczepaniak Sloane, Michael G White, Russell G Witt, et al.

Pageof 9

Showing results (41-50 of 85) with videos related to

Sort By:

Pageof 9

Annals of Surgical Oncology|May 26, 2026

The Role of Adjuvant Primary Site Radiotherapy for Cutaneous Melanoma Patients with MicrosatellitosisAnjali Devireddy, Yifan Yi, Kelsey N Nordlund, et al.

Cancer|December 3, 2016

Clinicopathological features and clinical outcomes associated with TP53 and BRAF<sup>N</sup><sup>on-</sup><sup>V</sup><sup>600</sup> mutations in cutaneous melanoma patientsDae Won Kim, Lauren E Haydu, Aron Y Joon, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2020

Circulating Tumor Cells and Early Relapse in Node-positive MelanomaAnthony Lucci, Carolyn S Hall, Sapna P Patel, et al.

Oncoimmunology|August 15, 2025

Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanomaMerve Hasanov, Simin Kiany, Marie-Andrée Forget, et al.

Journal for Immunotherapy of Cancer|May 22, 2021

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanomaChantal Saberian, Rodabe N Amaria, Amer M Najjar, et al.

Cancer Discovery|March 3, 2018

A Preexisting Rare <i>PIK3CA</i><sup>E545K</sup> Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in <i>NRAS</i> Melanoma and Is Dependent on S6K1 SignalingGabriele Romano, Pei-Ling Chen, Ping Song, et al.

Nutrients|January 10, 2026

Investigating Chronic Toxicity, Diet, Patient-Reported Outcomes and the Microbiome in Immunotherapy-Treated Metastatic Melanoma Survivors: A New FrontierMargaux Robert, Satabdi Saha, Nazli Dizman, et al.

Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 15, 2018

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal MelanomaRené J Tavera, Marie-Andrée Forget, Young Uk Kim, et al.

Annals of Surgical Oncology|March 16, 2026

Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal DissectionJoshua Herb, Roland L Bassett, Carlos A Torres-Cabala, et al.

Cancers|November 13, 2021

Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade OutcomesRobert A Szczepaniak Sloane, Michael G White, Russell G Witt, et al.

Pageof 9